Marker Therapeutics gets FDA approval for MT-601 IND in r/r NHL
Marker Therapeutics said that the US Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for MT-601 for the treatment of relapsed/refractory (r/r) non-Hodgkin lymphoma (NHL). The IND is for the multi-tumor-associated antigen (multiTAA)-specific T cell product to be used in relapsed/refractory non-Hodgkin lymphoma patients who either failed or are not […]